Brought to you by 
AxoGen sells future royalties to PDL BioPharma for $20.8mm; finalized at $30.3mm
13 Sep 2018
Executive Summary
In return for future high single-digit royalties on some of its net revenues during the next eight years, AxoGen Inc. (grafts and other products to protect and regenerate peripheral nerves) has received $20.8mm from antibody humanization company PDL BioPharma Inc. (generates most of its revenues through royalties on drugs that incorporate its technology). The placement agents were JMP Securities and Noble Financial Capital Markets.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
- Implantable Devices
Deal Status
- Final
Deal Type
-
Financing
- Royalty Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AxoGen sells future royalties to PDL BioPharma for $20.8mm; finalized at $30.3mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice